BioTek Receives LanthaScreen™ Plus Certification from Invitrogen™ for Multi-Mode Microplate Readers

May 16, 2008, WINOOSKI VT, USA — BioTek Instruments Inc., announced that it was awarded the LanthaScreen™ Certified Plus designation from Invitrogen Corporation, a provider of essential life science technologies for research, production and diagnostics. The LanthaScreen™ Certified Plus mark ensures that BioTek’s Synergy™ 4 and Synergy™ 2 multi-mode microplate readers are validated to strict standards in instrument setup and assay performance. LanthaScreen™ technology uses time-resolved fluorescence resonance energy transfer (TR-FRET) to study multiple target classes including protein kinases, nuclear hormone receptors, as well as proteases and ubiquitinated proteins. BioTek’s recently introduced patent-pending Synergy™ 4 Hybrid Microplate Reader is the first multi-mode reader to combine sensitive filter-based and flexible quadruple monochromator-based fluorescence detection technology in one compact unit. Using this Hybrid Technology™, customers can now benefit from endless flexibility and true multi-detection for an unlimited number of current and future microplate-based assays. In addition, Synergy 4 includes Fluorescence Intensity, Luminescence, Fluorescence Polarization, Time-Resolved Fluorescence, and UV-Visible Absorbance. The Synergy 2 Multi-Mode Microplate Reader is a modular reader incorporating detection modes for Fluorescence Intensity, Fluorescence Polarization, Time Resolved Fluorescence, Luminescence and UV-visible Absorbance. Synergy 2 uses a unique combination of monochromator, filters, and dichroic mirrors and three broad-spectrum light sources for optimal illumination that provide the best possible level of performance in all detection modes without performance degradation. BioTek Instruments, Inc., headquartered in Winooski, VT, is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. The BioTek Instruments, Inc. instrumentation is used to accelerate the drug discovery process, to advance discoveries in genomics and proteomics, and to aid in the advancement of life science research. For more information, visit

< | >